DFT and molecular simulation validation of the binding activity of PDEδ inhibitors for repression of oncogenic k-Ras

Taghreed A Majrashi1, Ahmed Sabt2, Hadia Almahli3

  • 1Department of Pharmacognosy, College of Pharmacy, King Khalid University, Asir, Saudi Arabia.

Plos One
|March 8, 2024
PubMed

Insights

Researchers explored K-Ras inhibitors and their interaction with PDEδ, a KRAS transporter. Computational methods revealed binding modes, aiding the development of novel anticancer drugs targeting K-Ras signaling.

Area of Science:

  • Oncology
  • Computational Chemistry
  • Structural Biology

Background:

  • Targeting the K-Ras oncogene is crucial for anticancer drug development.
  • PDEδ, a KRAS transporter, is a promising target for inhibiting oncogenic KRAS signaling.
  • Existing Ras signaling inhibitors have shown limited success.

Purpose of the Study:

  • To investigate the binding interactions between eight K-Ras inhibitors and PDEδ.
  • To understand the binding modes and mechanisms of PDEδ selective inhibition.
  • To computationally predict the efficacy of K-Ras inhibitors.

Main Methods:

  • Density Functional Theory (DFT)
  • Molecular Electrostatic Surface Potential (MESP)
  • Molecular docking and binding site analyses
  • Molecular Dynamic (MD) simulations
  • Binding free energy predictions (MMPB(GB)SA)

Main Results:

  • Detailed binding conformations and pharmacophoric features of inhibitors within the PDEδ active site were predicted.
  • Computational predictions of binding free energies were correlated with observed compound potency.
  • Understanding of the PDEδ selective inhibition mechanism was enhanced.

Conclusions:

  • Computational approaches provide valuable insights into K-Ras inhibitor-PDEδ interactions.
  • This study contributes to the rational design of novel, selective PDEδ inhibitors for K-Ras targeted cancer therapy.